Kano Therapeutics is a founder-led biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them, empowering scientists, labs, and companies with the building blocks they need to cross the chasm to cures.